Pfizer has officially thrown its hat in the weight-loss ring. The company’s GLP-1 receptor agonist, danuglipron, showed promise in an ongoing pharmacokinetic study, it announced Thursday. Pfizer plans ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results